//
Tengteng Yu
Mu Hao
Hailin Chen
Kenneth Wen
Tingjian Wang
Thomas C.M Smits
Mehmet K. Samur
Eugenio Morelli
Lijie Xing
Liang Lin
Jun Qi
Gang An
Nikhil C Munshi
Yu-Tzu Tai
Lugui Qiu
Kenneth C. Anderson
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
United States
China
N/A
Oncology (ONC)
Multiple Myeloma
B-cell lymphoma-extra large
B-cell lymphoma 2
Natural Killer cells
Peripheral blood mononuclear cell
Cluster of Differentiation 107 Antigen-Like Family Member A
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Cluster of Differentiation 2AP
Cyclin D1
Cyclin D2
Cluster of Differentiation 38
Programmed death-ligand 1
Interferon-alpha
Interferon-gamma
Interleukin 10
Signal Transducer And Activator Of Transcription 1
PI3K/AKT
daratumumab Intravenous
Isatuximab
Interferon
Interferon Gamma
IFN-lambda
Interleukin-10
N/A
N/A
NA
N/A
N/A
N/A